Charles River Laboratories (CRL)
NYSE: CRL · Life Sciences Tools & Services · Wilmington, MA
Our rating: Neutral
Neutral reaffirmed at $313.02, moderate conviction, November 5, 2026.
Breaks if: The Neutral call turns Cautious if free cash flow falls below $500M on a trailing twelve-month basis for two consecutive quarterly filings — that would signal the cash-generation thesis is impaired, not just the accounting line. It turns Positive if revenue returns to growth above 3% year-on-year while net income turns positive within the next two quarterly reports, confirming that the cycle has genuinely turned.
Key figures
| Market value | $15.1B |
|---|---|
| Revenue, last 12 months | $4.0B |
| Net income, last 12 months | $40M |
| Free cash flow, last 12 months | $400M |
| Price to earnings | 374.8× |
| Free cash flow yield | 2.7% |
| Dividend yield | 0.0% |
| Operating margin | 4.0% |
| Return on equity | 1.2% |
| Beta to the S&P 500 | 1.31 |
| Volatility, annualized | 49.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 26, 2026 | $983M | −2.2% | $6.86 | $207M |
| June 27, 2026 | $1.0B | −2.7% | $-0.03 | $149M |
| March 28, 2026 | $996M | 1.2% | $-0.30 | −$15M |
| December 27, 2025 | $994M | −0.8% | $-5.56 | $59M |
| September 27, 2025 | $1.0B | −0.5% | $1.10 | $178M |
| June 28, 2025 | $1.0B | 0.6% | $1.06 | $169M |
| March 29, 2025 | $984M | −2.7% | $0.50 | $112M |
| December 28, 2024 | $1.0B | −1.1% | $-4.17 | $84M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.98B: Claude 62%, Gemini 90%, Mistral 85%
- Diluted earnings per share are above zero: Claude 72%, Gemini 70%, Mistral 30%
- Free cash flow for the quarter is at least $0.06B: Claude 65%, Gemini 95%, Mistral 80%
- Backlog at the end of the quarter is at least $0.68B: Claude 40%, Gemini 45%, Mistral 50%
20 ledger entries and 40 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.